Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Targeting RNA to lower triglycerides: long strides from short molecules

Open access
Qamar, Arman, Libby, Peter, Bhatt, Deepak L · 2019 · European Heart Journal

Abstract

This editorial refers to ‘N-Acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides, and atherogenic lipoprotein levels’†, by V.J. Alexander et al., on page 2785. Despite remarkable progress in the prevention of atherothrombosis through lowering of LDL cholesterol (LDL-C), considerable cardiovascular risk remains. Triglycerides have gained renewed recognition as a marker of residual risk in patients with atherosclerotic cardiovascular disease (ASCVD) and in those with cardiometabolic risk factors.1 Several studies have shown an independent association of elevated triglycerides with an increased risk of cardiovascular events, even among patients with low LDL-C (<1.8 mmol/L or <70 mg/dL) treated with high-intensity statin therapy.2 Furthermore, recent genome-wide association studies and Mendelian randomization analyses support a causal role for triglyceride-rich lipoproteins (TRLs) in events due to coronary artery disease (CAD).3–5 For example, carriers of mutations that result in lifetime low levels of triglycerides have reduced risk of CAD. These observations support targeting triglycerides for reduction of cardiovascular risk. The recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) furnished further support for the ‘triglyceride-lowering hypothesis’.6 In REDUCE-IT, 8179 patients with established cardiovascular disease, or with risk factors, elevated triglycerides (>1.5 mmol/L or >135 mg/dL), and optimal LDL-C (1.0–2.6 mmol/L or 40–100 mg/dL) on background statin therapy randomly received 2 g twice daily of icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid that lowers triglycerides, or placebo. Relative to placebo, icosapent ethyl decreased triglycerides by ∼20%, the risk of ischaemic events including cardiovascular death by 25%, and total ischaemic events by 30% during the median follow-up of 4.9 years.7 , 8 Lowering of triglycerides probably contributed to the substantial benefit of icosapent ethyl in reducing ischaemic events in REDUCE-IT, in addition to other effects on prevention of atherothrombosis. Notably, most randomized clinical trials of drugs that lower triglycerides (i.e. fibrates, niacin, and omega-3 fatty acids except icosapent ethyl 4 g/day) have not shown reduction in cardiovascular events in statin-treated patients.1 Thus, despite the increased cardiovascular risk associated with triglycerides >1.1 mmol/L (>100 mg/dL), current guidelines only recommend pharmacological treatment for elevated triglycerides for severe hypertriglyceridaemia to prevent pancreatitis.9 , 10 Advancements in human genetics over the last decade have broadened our understanding of mechanisms of association of triglycerides with CAD.11 These developments have resulted in the discovery of novel pathways that regulate triglyceride levels, including apolipoprotein C3 (APOC3), angiopoietin-like 3, and angiopoietin-like 4, proteins currently under evaluation to lower triglycerides and reduce cardiovascular risk.11 APOC3 is a small apolipoprotein (79 amino acids) encoded by the APOC3 gene. Produced predominantly in the liver, APOC3 circulates attached to atherogenic TRLs such as very-low-density lipoprotein (VLDL), chylomicrons, and remnant cholesterol (Figure 1).12 Several studies have identified APOC3 as a key regulator of TRL metabolism. APOC3 increases levels of triglycerides by inhibiting the catabolism of TRLs by lipoprotein lipase and hepatic lipase, and by delaying remnant TRL clearance.11 , 12 Recent studies have associated loss-of-function variants in the APOC3 gene with decreased levels of APOC3, low triglycerides, and reduced risk of CAD.3 , 4 Elevated APOC3 levels are associated with an increased level of triglycerides, VLDLs, chylomicrons, remnant cholesterol, inflammation, and higher cardiovascular risk.13 Therefore, evidence thus far points to reduction of APOC3 as a promising therapeutic approach to lower triglycerides and reduce cardiovascular risk. To this end, an antisense oligonucleotide developed to target APOC3 mRNA lowers triglycerides by reducing APOC3 protein synthesis in the liver. As explained below, the advent of a selective strategy for targeting the liver in late-generation antisense oligonucleotides has markedly lowered the doses required to block the synthesis of proteins produced in hepatocytes and thus offers considerably improved tolerability of these agents. Relationship of APOC3 with triglycerides and coronary heart disease risk and the favourable cardiometabolic effects of APOC3 mRNA inhibition with an APOC3 antisense oligonucleotide. ApoB, apolipoprotein B; APOC3, apolipoprotein C3; ASO, antisense oligonucleotide; CHD, coronary heart disease; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; VLDL-C, very-low-density lipoprotein cholesterol. Advances in genetic technology have enabled targeting of disease-associated mRNAs.14 Antisense oligonucleotides consist of nucleotides complementary to the mRNA encod

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz321

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relationship of APOC3 with triglycerides and coronary heart disease risk and the favourable cardiometabolic effects of APOC3 mRNA inhibition with an APOC3 antisense oligonucleotide. ApoB, apolipoprotein B; APOC3, apolipoprotein C3; ASO, antisense oligonucleotide; CHD, coronary heart disease; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.
Figure 1 Relationship of APOC3 with triglycerides and coronary heart disease risk and the favourable cardiometabolic effects of APOC3 mRNA inhibition with an APOC3 antisense oligonucleotide. ApoB, apolipoprotein B; APOC3, apolipoprotein C3; ASO, antisense oligonucleotide; CHD, coronary heart disease; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 14

Metadata

Authors
Qamar, A., Libby, P., & Bhatt, D. L.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Bhatt, Deepak L
Venue
European Heart Journal
Published
2019-05-15
Volume
40
Issue
33
Pages
2797-2800
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2945876616
Cited by
14
References
19
Citations by year
2026: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 2
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • NHLBI T32 (T32HL007604)
  • American Heart Association Strategically Focused Research Network in Vascular Disease grant (18SFRN3390085, 18SFRN33960262)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
triglyceride lowering, triglyceride-rich lipoproteins, atherothrombosis, cardiovascular risk, icosapent ethyl, REDUCE-IT trial, omega-3 fatty acids, residual cardiovascular risk, atherosclerotic cardiovascular disease, LDL cholesterol
MeSH terms
Galactosamine, Lipoproteins, RNA, RNA, Messenger, Triglycerides, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RNA to lower triglycerides: long strides from short molecules. https://app.cochat.ai/papers/10.1093/eurheartj/ehz321
The paper
Qamar, A., Libby, P., & Bhatt, D. L. (2019). Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.